Blackstone Life Sciences is providing $750 million to Johnson & Johnson for the Phase 3 development of OLN324, a retinal disease therapy. This funding is contingent on J&J's acquisition of Ollin Biosciences and grants Blackstone milestone payments and single-digit royalties, signaling a significant biotech investment and potential future revenue streams for both parties.
Blackstone Life Sciences has committed $750 million to fund the Phase 3 clinical development of OLN324, a therapy for retinal vascular diseases, for Johnson & Johnson. This significant investment is conditional on J&J completing its acquisition of Ollin Biosciences, Inc., which likely owns OLN324. For Blackstone, this represents a strategic bet on a late-stage pharmaceutical asset, offering potential returns through regulatory and sales milestones, plus single-digit royalties. For Johnson & Johnson, it de-risks the substantial R&D costs associated with Phase 3 trials for a potentially lucrative drug, allowing them to advance their pipeline with external capital. Short-term, this is a positive for JNJ as it secures funding. Long-term, success of OLN324 would be a significant revenue driver for JNJ and a profitable investment for BX. The key opportunity for traders lies in the potential future success of OLN324 and its impact on JNJ's pharmaceutical segment and BX's life sciences portfolio.